UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/562,698	05/10/2006	Jee Woo Lee	029310.57239US	4276
23911 CROWELL & I	7590 11/16/200 MORING LLP	EXAMINER		
INTELLECTUAL PROPERTY GROUP			O SULLIVAN, PETER G	
P.O. BOX 14300 WASHINGTON, DC 20044-4300			ART UNIT	PAPER NUMBER
			1621	
			MAIL DATE	DELIVERY MODE
			11/16/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/562,698	LEE ET AL.			
Office Action Summary	Examiner	Art Unit			
	Peter G. O'Sullivan	1621			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>28 Ju</u> This action is FINAL . 2b) ☑ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 15-29 is/are pending in the application 4a) Of the above claim(s) 18-21 is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 15-17 and 22-29 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or Application Papers 9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction	rn from consideration. relection requirement. r. epted or b) □ objected to by the Edrawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date See Continuation Sheet.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

Continuation of Attachment(s) 3). Information Disclosure Statement(s) (PTO/SB/08), Paper No(s)/Mail Date :01/29/2009, 02/02/2007, 12/30/2005.

Claims 15-29 are pending in this application which should be reviewed for errors. In response to the restriction requirement, applicants elect compounds wherein A is an amide group, with traverse. Upon reconsideration, the restriction requirement is withdrawn. Upon the further requirement for the election of a single disclosed species, applicants elected N-(4-tert-butylbenzyl)-2-[3-fluoro-4]methylsulfonylamino) phenyl]propionamide. Accordingly, claims 18-21 are withdrawn from consideration.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 15-17 and 22-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Suh et al., WO 2002/016318. Suh et al. disclose modulators of vanilloid receptors useful for the treatment of pain, asthma, etc. given by their formula I, s. page 2, left column. X may be O, Y may be a single bond, R represents optionally

Application/Control Number: 10/562,698 Page 3

Art Unit: 1621

2002.

methansulfonylamino substituted phenylalkyl and R 2 may be R8-(CH2)n-. Applicants' attention is drawn to extremely close examples 193 and 168 which differ from applicants' compounds by a methylene group. It would have been prima facie obvious at the time the invention was made to one of ordinary skill in the art to start with the teaching of Suh et al., to make generically disclosed compounds overlapping applicants especially in view of close compounds already made and to expect them to be useful in the treatment of pain, asthma, etc. Suh et al. has a publication date of 28 February

No claim is allowed.

Any inquiry concerning this communication should be directed to Peter G. O'Sullivan at telephone number (571)272-0642.

/Peter G O'Sullivan/

Primary Examiner, Art Unit 1621